SSA
APGN

Schonfeld Strategic Advisors’s Apexigen, Inc. Common Stock APGN Stock Holding History

Schonfeld Strategic Advisors’s Portfolio APGN Stock Details APGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-28,809
Closed -$293K – 3285
2022
Q2 		$293K Buy
28,809
+3,679
+15% +$37.2K ﹤0.01% 1690
2022
Q1 		$253K Buy
25,130
+2,245
+10% +$22.5K ﹤0.01% 1790
2021
Q4 		$229K Buy
22,885
+7,317
+47% +$72.9K ﹤0.01% 1661
2021
Q3 		$155K Buy
+15,568
New +$154K ﹤0.01% 1837

Other funds holding APGN

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Schonfeld Strategic Advisors's APGN Position: Q3 2022 in Review

Schonfeld Strategic Advisors sold out of Apexigen, Inc. Common Stock (APGN) in Q3 2022, closing a stake of 28,809 shares — an estimated $293K sold.

Schonfeld Strategic Advisors first reported a position in APGN in Q3 2021 and held it in 4 quarters. The position peaked at $293K in Q2 2022. 18 funds tracked by Wall St. Rank hold APGN as of Q3 2022.

  • Schonfeld Strategic Advisors reported no remaining Apexigen, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 28,809 Apexigen, Inc. Common Stock shares in Q3 2022, an estimated $293K.
  • Schonfeld Strategic Advisors first reported a position in Apexigen, Inc. Common Stock in Q3 2021 and held it in 4 quarters.
  • Schonfeld Strategic Advisors's Apexigen, Inc. Common Stock position peaked at $293K in Q2 2022.
  • 18 funds tracked by Wall St. Rank held Apexigen, Inc. Common Stock as of Q3 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.